Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A Rapid Method for the Detection of Sarcosine Using SPIONs/Au/CS/SOX/NPs for Prostate Cancer Sensing

D. Uhlirova, M. Stankova, M. Docekalova, B. Hosnedlova, M. Kepinska, B. Ruttkay-Nedecky, J. Ruzicka, C. Fernandez, H. Milnerowicz, R. Kizek,

. 2018 ; 19 (12) : . [pub] 20181122

Language English Country Switzerland

Document type Journal Article

BACKGROUND: Sarcosine is an amino acid that is formed by methylation of glycine and is present in trace amounts in the body. Increased sarcosine concentrations in blood plasma and urine are manifested in sarcosinemia and in some other diseases such as prostate cancer. For this purpose, sarcosine detection using the nanomedicine approach was proposed. In this study, we have prepared superparamagnetic iron oxide nanoparticles (SPIONs) with different modified surface area. Nanoparticles (NPs) were modified by chitosan (CS), and sarcosine oxidase (SOX). SPIONs without any modification were taken as controls. Methods and Results: The obtained NPs were characterized by physicochemical methods. The size of the NPs determined by the dynamic light scattering method was as follows: SPIONs/Au/NPs (100⁻300 nm), SPIONs/Au/CS/NPs (300⁻700 nm), and SPIONs/Au/CS/SOX/NPs (600⁻1500 nm). The amount of CS deposited on the NP surface was found to be 48 mg/mL for SPIONs/Au/CS/NPs and 39 mg/mL for SPIONs/Au/CS/SOX/NPs, and repeatability varied around 10%. Pseudo-peroxidase activity of NPs was verified using sarcosine, horseradish peroxidase (HRP) and 3,3',5,5'-tetramethylbenzidine (TMB) as a substrate. For TMB, all NPs tested evinced substantial pseudo-peroxidase activity at 650 nm. The concentration of SPIONs/Au/CS/SOX/NPs in the reaction mixture was optimized to 0⁻40 mg/mL. Trinder reaction for sarcosine detection was set up at 510 nm at an optimal reaction temperature of 37 °C and pH 8.0. The course of the reaction was linear for 150 min. The smallest amount of NPs that was able to detect sarcosine was 0.2 mg/well (200 µL of total volume) with the linear dependence y = 0.0011x - 0.0001 and the correlation coefficient r = 0.9992, relative standard deviation (RSD) 6.35%, limit of detection (LOD) 5 µM. The suggested method was further validated for artificial urine analysis (r = 0.99, RSD 21.35%, LOD 18 µM). The calculation between the detected and applied concentrations showed a high correlation coefficient (r = 0.99). NPs were tested for toxicity and no significant growth inhibition was observed in any model system (S. cerevisiae, S. aureus, E. coli). The hemolytic activity of the prepared NPs was similar to that of the phosphate buffered saline (PBS) control. The reaction system was further tested on real urine specimens. Conclusion: The proposed detection system allows the analysis of sarcosine at micromolar concentrations and to monitor changes in its levels as a potential prostate cancer marker. The whole system is suitable for low-cost miniaturization and point-of-care testing technology and diagnostic systems. This system is simple, inexpensive, and convenient for screening tests and telemedicine applications.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012122
003      
CZ-PrNML
005      
20191004075917.0
007      
ta
008      
190405s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms19123722 $2 doi
035    __
$a (PubMed)30467297
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Uhlirova, Dagmar $u Department of Research and Development, Prevention Medicals, Tovarni 342, 742 13 Studenka-Butovice, Czech Republic. dagmar.uhlirova@seznam.cz.
245    12
$a A Rapid Method for the Detection of Sarcosine Using SPIONs/Au/CS/SOX/NPs for Prostate Cancer Sensing / $c D. Uhlirova, M. Stankova, M. Docekalova, B. Hosnedlova, M. Kepinska, B. Ruttkay-Nedecky, J. Ruzicka, C. Fernandez, H. Milnerowicz, R. Kizek,
520    9_
$a BACKGROUND: Sarcosine is an amino acid that is formed by methylation of glycine and is present in trace amounts in the body. Increased sarcosine concentrations in blood plasma and urine are manifested in sarcosinemia and in some other diseases such as prostate cancer. For this purpose, sarcosine detection using the nanomedicine approach was proposed. In this study, we have prepared superparamagnetic iron oxide nanoparticles (SPIONs) with different modified surface area. Nanoparticles (NPs) were modified by chitosan (CS), and sarcosine oxidase (SOX). SPIONs without any modification were taken as controls. Methods and Results: The obtained NPs were characterized by physicochemical methods. The size of the NPs determined by the dynamic light scattering method was as follows: SPIONs/Au/NPs (100⁻300 nm), SPIONs/Au/CS/NPs (300⁻700 nm), and SPIONs/Au/CS/SOX/NPs (600⁻1500 nm). The amount of CS deposited on the NP surface was found to be 48 mg/mL for SPIONs/Au/CS/NPs and 39 mg/mL for SPIONs/Au/CS/SOX/NPs, and repeatability varied around 10%. Pseudo-peroxidase activity of NPs was verified using sarcosine, horseradish peroxidase (HRP) and 3,3',5,5'-tetramethylbenzidine (TMB) as a substrate. For TMB, all NPs tested evinced substantial pseudo-peroxidase activity at 650 nm. The concentration of SPIONs/Au/CS/SOX/NPs in the reaction mixture was optimized to 0⁻40 mg/mL. Trinder reaction for sarcosine detection was set up at 510 nm at an optimal reaction temperature of 37 °C and pH 8.0. The course of the reaction was linear for 150 min. The smallest amount of NPs that was able to detect sarcosine was 0.2 mg/well (200 µL of total volume) with the linear dependence y = 0.0011x - 0.0001 and the correlation coefficient r = 0.9992, relative standard deviation (RSD) 6.35%, limit of detection (LOD) 5 µM. The suggested method was further validated for artificial urine analysis (r = 0.99, RSD 21.35%, LOD 18 µM). The calculation between the detected and applied concentrations showed a high correlation coefficient (r = 0.99). NPs were tested for toxicity and no significant growth inhibition was observed in any model system (S. cerevisiae, S. aureus, E. coli). The hemolytic activity of the prepared NPs was similar to that of the phosphate buffered saline (PBS) control. The reaction system was further tested on real urine specimens. Conclusion: The proposed detection system allows the analysis of sarcosine at micromolar concentrations and to monitor changes in its levels as a potential prostate cancer marker. The whole system is suitable for low-cost miniaturization and point-of-care testing technology and diagnostic systems. This system is simple, inexpensive, and convenient for screening tests and telemedicine applications.
650    _2
$a nádorové biomarkery $x moč $7 D014408
650    _2
$a chitosan $x chemie $7 D048271
650    _2
$a Escherichia coli $x účinky léků $x růst a vývoj $7 D004926
650    _2
$a železité sloučeniny $x chemie $7 D005290
650    _2
$a zlato $x chemie $7 D006046
650    _2
$a hemolýza $x účinky léků $7 D006461
650    _2
$a křenová peroxidasa $x chemie $7 D006735
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a limita detekce $7 D057230
650    _2
$a magnetické nanočástice $x chemie $x ultrastruktura $7 D058185
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a velikost částic $7 D010316
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a nádory prostaty $x diagnóza $x moč $7 D011471
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a Saccharomyces cerevisiae $x účinky léků $x růst a vývoj $7 D012441
650    _2
$a sarkosin $x moč $7 D012521
650    _2
$a sarkosinoxidasa $x chemie $7 D050879
650    _2
$a Staphylococcus aureus $x účinky léků $x růst a vývoj $7 D013211
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stankova, Martina $u Department of Research and Development, Prevention Medicals, Tovarni 342, 742 13 Studenka-Butovice, Czech Republic. MartStan@seznam.cz.
700    1_
$a Docekalova, Michaela $u Department of Research and Development, Prevention Medicals, Tovarni 342, 742 13 Studenka-Butovice, Czech Republic. MichaelaDocekalova@seznam.cz.
700    1_
$a Hosnedlová, Božena $7 xx0240321 $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic. bozena.hosnedlova@post.cz.
700    1_
$a Kepinska, Marta $u Department of Biomedical and Environmental Analyses, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland. zalewska.m@gmail.com.
700    1_
$a Ruttkay-Nedecký, Branislav $7 xx0237909 $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic. brano.ruttkay@seznam.cz.
700    1_
$a Ruzicka, Josef $u Department of Research and Development, Prevention Medicals, Tovarni 342, 742 13 Studenka-Butovice, Czech Republic. ruzicka.josef@iol.cz.
700    1_
$a Fernandez, Carlos $u School of Pharmacy and Life Sciences, Robert Gordon University, Garthdee Road, Aberdeen AB10 7QB, UK. c.fernandez@rgu.ac.uk.
700    1_
$a Milnerowicz, Halina $u Department of Biomedical and Environmental Analyses, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland. halina.milnerowicz@umed.wroc.pl.
700    1_
$a Kizek, Rene $u Department of Research and Development, Prevention Medicals, Tovarni 342, 742 13 Studenka-Butovice, Czech Republic. kizek@sci.muni.cz. Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic. kizek@sci.muni.cz. Department of Biomedical and Environmental Analyses, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland. kizek@sci.muni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 19, č. 12 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30467297 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20191004080327 $b ABA008
999    __
$a ok $b bmc $g 1391432 $s 1050427
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 12 $e 20181122 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...